Last update 01 Jul 2024
Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8(NCI)
Last update 01 Jul 2024
Overview
Basic Info
Drug Type Radiolabeled antibody, Diagnostic radiopharmaceuticals |
Synonyms- |
Target |
Mechanism CD45 inhibitors(Leukocyte common antigen inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Structure
Boost your research with our XDC technology data.
login
or
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| B-cell lymphoma recurrent | Phase 2 | US | 09 Oct 2013 | |
| B-cell lymphoma refractory | Phase 2 | US | 09 Oct 2013 | |
| Mantle cell lymphoma recurrent | Phase 2 | US | 09 Oct 2013 | |
| Mantle cell lymphoma refractory | Phase 2 | US | 09 Oct 2013 | |
| Recurrent Hodgkin Lymphoma | Phase 2 | US | 09 Oct 2013 | |
| Refractory Hodgkin Lymphoma | Phase 2 | US | 09 Oct 2013 | |
| T-cell lymphoma recurrent | Phase 2 | US | 09 Oct 2013 | |
| T-cell lymphoma refractory | Phase 2 | US | 09 Oct 2013 | |
| Multiple Myeloma | Phase 1 | US | 09 Jan 2012 | |
| Anemia, Refractory, With Excess of Blasts | Phase 1 | US | 01 Jan 2012 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 15 | tumrjqjpgp(tsowfvztfr) = pcoofjtnsg cetdhbiobf (lwobusuqgm ) View more | - | 24 Jul 2020 | |||
Phase 1 | 16 | aiihlhsqsm(aehfdwmdbx) = yntrnqcphr lnwvkpikqj (wrhuzbirdh ) View more | - | 01 Jun 2020 | |||
Fludarabine and 2 Gy total body irradiation | pmpfcpdlpo(bidsjxqoij) = ggoxyduibg smkhnggrxs (yjqiczridu ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free